Access cutting-edge plaque psoriasis, psoriatic arthritis, crohn's disease, or other conditions for which risankizumab is an fda-approved treatment treatment through this clinical trial at a research site in Wilmington. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Wilmington location
Preparing your pre-screening questions…
Access plaque psoriasis, psoriatic arthritis, crohn's disease, or other conditions for which risankizumab is an fda-approved treatment specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related plaque psoriasis, psoriatic arthritis, crohn's disease, or other conditions for which risankizumab is an fda-approved treatment treatment provided free
Check if you qualify for this plaque psoriasis, psoriatic arthritis, crohn's disease, or other conditions for which risankizumab is an fda-approved treatment clinical trial in Wilmington, NC
No-Cost Study Care
Local to Wilmington
Convenient for NC residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease (CD), or other conditions for which risankizumab is an FDA-approved treatment. The registry is designed to estimate the association between risankizumab and maternal, fetal, and infant outcomes by comparing the prevalence rates of these outcomes in the exposed and unexposed populations. Approximately 818 female participants with pregnancy will be enrolled (409 participants exposed to risankizumab and 409 without exposure) at multiple sites across the United States. Participants will not receive risankizumab as part of this study. Maternal and fetal outcomes during pregnancy for female participants who received risankizumab or other treatment will be followed for and up to 1 year after delivery There may be a higher burden for participants in this study compared to standard of care. Participants will attend visits determined by HCPs during the study at a hospital or clinic. The pregnancy outcomes including side effects will be collected during routine clinical care.
Sponsor: AbbVie
Yes, this clinical trial (NCT04846959) has an active research site in Wilmington, NC that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for plaque psoriasis, psoriatic arthritis, crohn's disease, or other conditions for which risankizumab is an fda-approved treatment treatment options in Wilmington, NC, this clinical trial (NCT04846959) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Wilmington research site is actively enrolling participants for this clinical trial. You'll receive care from experienced plaque psoriasis, psoriatic arthritis, crohn's disease, or other conditions for which risankizumab is an fda-approved treatment specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all plaque psoriasis, psoriatic arthritis, crohn's disease, or other conditions for which risankizumab is an fda-approved treatment clinical trials near you to find additional studies recruiting in your area.
See all psoriasis clinical trials recruiting in Wilmington — not just this study.
Browse Psoriasis Trials in Wilmington →